Development of new drugs for an old target - The penicillin binding proteins

Molecules

Volumn 17, Issue 11, 2012, Pages 12478-12505

  Zervosen, Astrid ^a   Sauvage, Eric ^a   Frère, Jean Marie ^a   Charlier, Paulette ^a   Luxen, André ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

lactam resistance; Inhibitors; Non lactam; Penicillin binding protein; Substrate analogs; Transition state analogs

Indexed keywords

ANTIINFECTIVE AGENT; BETA LACTAMASE; ENZYME INHIBITOR; PENICILLIN BINDING PROTEIN; PENICILLIN DERIVATIVE;

ANIMAL; BACTERIUM; CHEMISTRY; DRUG ANTAGONISM; DRUG DEVELOPMENT; DRUG EFFECT; ENZYME ACTIVE SITE; ENZYME ASSAY; HUMAN; MICROBIAL SENSITIVITY TEST; PENICILLIN RESISTANCE; PROTEIN BINDING; REVIEW;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIA; BETA-LACTAMASES; CATALYTIC DOMAIN; DRUG DISCOVERY; ENZYME ASSAYS; ENZYME INHIBITORS; HUMANS; MICROBIAL SENSITIVITY TESTS; PENICILLIN RESISTANCE; PENICILLIN-BINDING PROTEINS; PENICILLINS; PROTEIN BINDING;

EID: 84870218839     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules171112478     Document Type: Review

References (106)

1. Papp-Wallace, K.M.; Endimiani, A.; Taracila, M.A.; Bonomo, R.A. Carbapenems: Past, Present, And future. Antimicrob. Agents Ch. 2011, 55, 4943-4960.
2. Demain, A.L.; Sanchez, S. Microbial drug discovery: 80 Years of progress. J. Antibiot. 2009, 62, 5-16.
3. Rammelkamp, C.H.; Maxon, T. Resistance of Staphylococcus aureus to the Action of Penicillin. Proc. Soc. Exp. Biol. Med. 1942, 51, 386-389.
4. Jovetic, S.; Zhu, Y.; Marcone, G.L.; Marinelli, F.; Tramper, J. beta-Lactam and glycopeptide antibiotics: First and last line of defense? Trends Biotechnol. 2010, 28, 596-604.
5. Chambers, H.F. Methicillin resistance in staphylococci: Molecular and biochemical basis and clinical implications. Clin. Microbiol. Rev. 1997, 10, 781-791.
6. Drawz, S.M.; Bonomo, R.A. Three decades of beta-lactamase inhibitors. Clin. Microbiol. Rev. 2010, 23, 160-201.
7. Barlow, M. What antimicrobial resistance has taught us about horizontal gene transfer. Methods Mol. Biol. 2009, 532, 397-411.
8. Pernot, L.; Chesnel, L.; Le Gouellec, A.; Croize, J.; Vernet, T.; Dideberg, O.; Dessen, A. A PBP2x from a clinical isolate of Streptococcus pneumoniae exhibits an alternative mechanism for reduction of susceptibility to beta-lactam antibiotics. J. Biol. Chem. 2004, 279, 16463-16470.
9. Brannigan, J.A.; Tirodimos, I.A.; Zhang, Q.Y.; Dowson, C.G.; Spratt, B.G. Insertion of an extra amino acid is the main cause of the low affinity of penicillin-binding protein 2 in penicillin-resistant strains of Neisseria gonorrhoeae. Mol. Microbiol. 1990, 4, 913-919.
10. Dabernat, H.; Delmas, C.; Seguy, M.; Pelissier, R.; Faucon, G.; Bennamani, S.; Pasquier, C. Diversity of beta-lactam resistance-conferring amino acid substitutions in penicillin-binding protein 3 of Haemophilus influenzae. Antimicrob. Agents Ch. 2002, 46, 2208-2218.
11. Hakenbeck, R. beta-lactam-resistant Streptococcus pneumoniae: Epidemiology and evolutionary mechanism. Chemotherapy 1999, 45, 83-94.
12. Lambert, P.A. Bacterial resistance to antibiotics: Modified target sites. Adv. Drug Deliv. Rev. 2005, 57, 1471-1485.
13. Doumith, M.; Ellington, M.J.; Livermore, D.M.; Woodford, N. Molecular mechanisms disrupting porin expression in ertapenem-resistant Klebsiella and Enterobacter spp. clinical isolates from the UK. J. Antimicrob. Chemother. 2009, 63, 659-667.
14. Livermore, D.M. Of Pseudomonas, Porins, Pumps and carbapenems. J. Antimicrob. Chemother. 2001, 47, 247-250.
15. Livermore, D.M. Has the era of untreatable infections arrived? J. Antimicrob. Chemother. 2009, 64 (Suppl. 1), i29-i36.
16. Rice, L.B. The clinical consequences of antimicrobial resistance. Curr. Opin. Microbiol. 2009, 12, 476-481.
17. Aarestrup, F. Sustainable farming: Get pigs off antibiotics. Nature 2012, 486, 465-466.
18. Infectious Diseases Society of America. The 10 x '20 Initiative: Pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin. Infect. Dis. 2010, 50, 1081-1083.
19. Devasahayam, G.; Scheld, W.M.; Hoffman, P.S. Newer antibacterial drugs for a new century. Expert Opin. Inv. Drugs 2010, 19, 215-234.
20. Courvalin, P. Predictable and unpredictable evolution of antibiotic resistance. J. Intern. Med. 2008, 264, 4-16.
21. Bebrone, C.; Lassaux, P.; Vercheval, L.; Sohier, J.S.; Jehaes, A.; Sauvage, E.; Galleni, M. Current challenges in antimicrobial chemotherapy: Focus on beta-lactamase inhibition. Drugs 2010, 70, 651-679.
22. Pratt, R.F. Beta-lactamase inhibitors: Non-beta-lactams. In Beta-lactamases; Frére, J.-M., Ed.; Nova Science Publisher, Inc: Hauppauge, NY, USA, 2012; pp. 259-292.
23. Coleman, K. Diazabicyclooctanes (DBOs): A potent new class of non-beta-lactam beta-lactamase inhibitors. Curr. Opin. Microbiol. 2011, 14, 550-555.
24. Endimiani, A.; Choudhary, Y.; Bonomo, R.A. In vitro activity of NXL104 in combination with beta-lactams against Klebsiella pneumoniae isolates producing KPC carbapenemases. Antimicrob. Agents Ch. 2009, 53, 3599-3601.
25. Stachyra, T.; Levasseur, P.; Pechereau, M.C.; Girard, A.M.; Claudon, M.; Miossec, C.; Black, M.T. In vitro activity of the {beta}-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases. J. Antimicrob. Chemother. 2009, 64, 326-329.
26. Llarrull, L.I.; Testero, S.A.; Fisher, J.F.; Mobashery, S. The future of the beta-lactams. Curr. Opin. Microbiol. 2010, 13, 551-557.
27. Theuretzbacher, U. Resistance drives antibacterial drug development. Curr. Opin. Pharmacol. 2011, 11, 433-438.
28. Queenan, A.M.; Shang, W.; Flamm, R.; Bush, K. Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. Antimicrob. Agents Ch. 2010, 54, 565-569.
29. Vidaillac, C.; Rybak, M.J. Ceftobiprole: First cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Pharmacotherapy 2009, 29, 511-525.
30. Laudano, J.B. Ceftaroline fosamil: A new broad-spectrum cephalosporin. J. Antimicrob. Chemoth. 2011, 66 (Suppl. 3), iii11-iii18.
31. Vidaillac, C.; Leonard, S.N.; Sader, H.S.; Jones, R.N.; Rybak, M.J. In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob. Agents Ch. 2009, 53, 2360-2366.
32. Sliwa, A.; Dive, G.; Habib Jiwan, J.-L.; Marchand-Brynaert, J. Cyclodimerization by ring-closing metathesis: Synthesis, Computational, And biological evaluation of novel bis-azetidinyl-macrocycles. Tetrahedron 2010, 66, 9519-9527.
33. Sliwa, A.; Dive, G.; Zervosen, A.; Verlaine, O.; Sauvage, E.; Marchand-Brynaert, J. Unprecedented inhibition of resistant penicillin binding proteins by bis-2-oxoazetidinyl macrocycles. Med. Chem. Commun. 2012, 3, 344-351.
34. Urbach, A.; Dive, G.; Marchand-Brynaert, J. Novel Large-Ring 1,3-Bridged 2-Azetidinones as Potential Inhibitors of Penicillin-Binding Proteins. Eur. J. Org. Chem. 2009, 2009, 1757-1770.
35. Urbach, A.; Dive, G.; Tinant, B.; Duval, V.; Marchand-Brynaert, J. Large ring 1,3-bridged 2-azetidinones: Experimental and theoretical studies. Eur. J. Med. Chem. 2009, 44, 2071-2080.
36. Lim, D.; Strynadka, N.C. Structural basis for the beta lactam resistance of PBP2a from methicillin-resistant Staphylococcus aureus. Nat. Struct. Biol. 2002, 9, 870-876.
37. Dessen, A.; Mouz, N.; Gordon, E.; Hopkins, J.; Dideberg, O. Crystal structure of PBP2x from a highly penicillin-resistant Streptococcus pneumoniae clinical isolate: A mosaic framework containing 83 mutations. J. Biol. Chem. 2001, 276, 45106-45112.
38. Sauvage, E.; Kerff, F.; Fonze, E.; Herman, R.; Schoot, B.; Marquette, J.P.; Taburet, Y.; Prevost, D.; Dumas, J.; Leonard, G.; et al. The 2.4-A crystal structure of the penicillin-resistant penicillin-binding protein PBP5fm from Enterococcus faecium in complex with benzylpenicillin. Cell. Mol. Life Sci. 2002, 59, 1223-1232.
39. Frere, J.M.; Marchot, P. Inactivators in competition: How to deal with them⋯ and not! Biochem. Pharmacol. 2005, 70, 1417-1423.
40. Frère, J.-M.; Nguyen-Disteche, M.; Coyette, J.; Joris, B. Mode of action: Interaction with penicillin binding proteins. In The Chemistry of beta-lactams; Page, M., Ed.; Chapman and Hall: Glasgow, Scotland, 1992; pp. 148-195.
41. Fuad, N.; Frere, J.M.; Ghuysen, J.M.; Duez, C.; Iwatsubo, M. Mode of interaction between beta-lactam antibiotics and the exocellular DD-carboxypeptidase - transpeptidase from Streptomyces R39. Biochem. J. 1976, 155, 623-629.
42. Jamin, M.; Damblon, C.; Millier, S.; Hakenbeck, R.; Frere, J.M. Penicillin-binding protein 2x of Streptococcus pneumoniae: Enzymic activities and interactions with beta-lactams. Biochem. J. 1993, 292, 735-741.
43. Jamin, M.; Hakenbeck, R.; Frere, J.M. Penicillin binding protein 2x as a major contributor to intrinsic beta-lactam resistance of Streptococcus pneumoniae. FEBS Lett. 1993, 331, 101-104.
44. Leyh-Bouille, M.; Nguyen-Disteche, M.; Pirlot, S.; Veithen, A.; Bourguignon, C.; Ghuysen, J.M. Streptomyces K15 DD-peptidase-catalysed reactions with suicide beta-lactam carbonyl donors. Biochem. J. 1986, 235, 177-182.
45. Lakaye, B.; Damblon, C.; Jamin, M.; Galleni, M.; Lepage, S.; Joris, B.; Marchand-Brynaert, J.; Frydrych, C.; Frere, J.M. Synthesis, Purification and kinetic properties of fluorescein-labelled penicillins. Biochem. J. 1994, 300, 141-145.
46. Zhao, G.; Meier, T.I.; Kahl, S.D.; Gee, K.R.; Blaszczak, L.C. BOCILLIN FL, A sensitive and commercially available reagent for detection of penicillin-binding proteins. Antimicrob. Agents Ch. 1999, 43, 1124-1128.
47. Dargis, M.; Malouin, F. Use of biotinylated beta-lactams and chemiluminescence for study and purification of penicillin-binding proteins in bacteria. Antimicrob. Agents Ch. 1994, 38, 973-980.
48. Toney, J.H.; Hammond, G.G.; Leiting, B.; Pryor, K.D.; Wu, J.K.; Cuca, G.C.; Pompliano, D.L. Soluble penicillin-binding protein 2a: Beta-lactam binding and inhibition by non-beta-lactams using a 96-well format. Anal. Biochem. 1998, 255, 113-119.
49. Stefanova, M.; Bobba, S.; Gutheil, W.G. A microtiter plate-based beta-lactam binding assay for inhibitors of high-molecular-mass penicillin-binding proteins. Anal. Biochem. 2010, 396, 164-166.
50. Bobba, S.; Ponnaluri, V.K.; Mukherji, M.; Gutheil, W.G. Microtiter plate-based assay for inhibitors of penicillin-binding protein 2a from methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Ch. 2011, 55, 2783-2787.
51. Inglis, S.R.; Strieker, M.; Rydzik, A.M.; Dessen, A.; Schofield, C.J. A boronic-acid-based probe for fluorescence polarization assays with penicillin binding proteins and beta-lactamases. Anal. Biochem. 2012, 420, 41-47.
52. Contreras-Martel, C.; Amoroso, A.; Woon, E.C.; Zervosen, A.; Inglis, S.; Martins, A.; Verlaine, O.; Rydzik, A.M.; Job, V.; Luxen, A.; et al. Structure-guided design of cell wall biosynthesis inhibitors that overcome beta-lactam resistance in Staphylococcus aureus (MRSA). ACS Chem. Biol. 2011, 6, 943-951.
53. Zervosen, A.; Bouillez, A.; Herman, A.; Amoroso, A.; Joris, B.; Sauvage, E.; Charlier, P.; Luxen, A. Synthesis and evaluation of boronic acids as inhibitors of Penicillin Binding Proteins of classes A, B and C. Bioorg. Med. Chem. 2012, 20, 3915-3924.
54. Zervosen, A.; Lu, W.P.; Chen, Z.; White, R.E.; Demuth, T.P., Jr.; Frere, J.M. Interactions between penicillin-binding proteins (PBPs) and two novel classes of PBP inhibitors, Arylalkylidene rhodanines and arylalkylidene iminothiazolidin-4-ones. Antimicrob. Agents Ch. 2004, 48, 961-969.
55. Adam, M.; Damblon, C.; Plaitin, B.; Christiaens, L.; Frere, J.M. Chromogenic Depsipeptide Substrates for Beta-Lactamases and Penicillin-Sensitive DD-Peptidases. Biochem. J. 1990, 270, 525-529.
56. Damblon, C.; Zhao, G.H.; Jamin, M.; Ledent, P.; Dubus, A.; Vanhove, M.; Raquet, X.; Christiaens, L.; Frere, J.M. Breakdown of the stereospecificity of DD-peptidases and beta-lactamases with thiolester substrates. Biochem. J. 1995, 309, 431-436.
57. Sauvage, E.; Zervosen, A.; Dive, G.; Herman, R.; Amoroso, A.; Joris, B.; Fonze, E.; Pratt, R.F.; Luxen, A.; Charlier, P.; et al. Structural basis of the inhibition of class A beta-lactamases and penicillin-binding proteins by 6-beta-iodopenicillanate. J. Am. Chem. Soc. 2009, 131, 15262-15269.
58. Zervosen, A.; Herman, R.; Kerff, F.; Herman, A.; Bouillez, A.; Prati, F.; Pratt, R.F.; Frere, J.M.; Joris, B.; Luxen, A.; et al. Unexpected tricovalent binding mode of boronic acids within the active site of a penicillin-binding protein. J. Am. Chem. Soc. 2011, 133, 10839-10848.
59. Gao, W.; Xing, B.; Tsien, R.Y.; Rao, J. Novel fluorogenic substrates for imaging beta-lactamase gene expression. J. Am. Chem. Soc. 2003, 125, 11146-11147.
60. Xing, B.; Khanamiryan, A.; Rao, J. Cell-permeable near-infrared fluorogenic substrates for imaging beta-lactamase activity. J. Am. Chem. Soc. 2005, 127, 4158-4159.
61. Zlokarnik, G.; Negulescu, P.A.; Knapp, T.E.; Mere, L.; Burres, N.; Feng, L.; Whitney, M.; Roemer, K.; Tsien, R.Y. Quantitation of transcription and clonal selection of single living cells with beta-lactamase as reporter. Science 1998, 279, 84-88.
62. Feng, B.Y.; Shoichet, B.K. A detergent-based assay for the detection of promiscuous inhibitors. Nat. Protoc. 2006, 1, 550-553.
63. Shoichet, B.K. Screening in a spirit haunted world. Drug Discov. Today 2006, 11, 607-615.
64. Kraut, J. Serine proteases: Structure and mechanism of catalysis. Annu. Rev. Biochem. 1977, 46, 331-358.
65. Mattei, P.J.; Neves, D.; Dessen, A. Bridging cell wall biosynthesis and bacterial morphogenesis. Curr. Opin. Struct. Biol. 2010, 20, 749-755.
66. Sauvage, E.; Kerff, F.; Terrak, M.; Ayala, J.A.; Charlier, P. The penicillin-binding proteins: Structure and role in peptidoglycan biosynthesis. FEMS Microbiol. Rev. 2008, 32, 234-258.
67. Pechenov, A.; Stefanova, M.E.; Nicholas, R.A.; Peddi, S.; Gutheil, W.G. Potential transition state analogue inhibitors for the penicillin-binding proteins. Biochemistry 2003, 42, 579-588.
68. Nicola, G.; Peddi, S.; Stefanova, M.; Nicholas, R.A.; Gutheil, W.G.; Davies, C. Crystal structure of Escherichia coli penicillin-binding protein 5 bound to a tripeptide boronic acid inhibitor: A role for Ser-110 in deacylation. Biochemistry 2005, 44, 8207-8217.
69. Dzhekieva, L.; Rocaboy, M.; Kerff, F.; Charlier, P.; Sauvage, E.; Pratt, R.F. Crystal structure of a complex between the Actinomadura R39 DD-peptidase and a peptidoglycan-mimetic boronate inhibitor: Interpretation of a transition state analogue in terms of catalytic mechanism. Biochemistry 2010, 49, 6411-6419.
70. Inglis, S.R.; Zervosen, A.; Woon, E.C.; Gerards, T.; Teller, N.; Fischer, D.S.; Luxen, A.; Schofield, C.J. Synthesis and evaluation of 3-(dihydroxyboryl)benzoic acids as D,D-carboxypeptidase R39 inhibitors. J. Med. Chem. 2009, 52, 6097-6106.
71. Woon, E.C.Y.; Zervosen, A.; Sauvage, E.; Simmons, K.J.; Zivec, M.; Inglis, S.R.; Fishwick, C.W.G.; Gobec, S.; Charlier, P.; Luxen, A.; et al. Structure Guided Development of Potent Reversibly Binding Penicillin Binding Protein Inhibitors. ACS Med. Chem. Lett. 2011, 2, 219-223.
72. Trippier, P.C.; McGuigan, C. Boronic acids in medicinal chemistry: Anticancer, Antibacterial and antiviral applications. Med. Chem. Commun. 2010, 1, 183-198.
73. Li, N.; Rahil, J.; Wright, M.E.; Pratt, R.F. Structure-activity studies of the inhibition of serine beta-lactamases by phosphonate monoesters. Bioorg. Med. Chem. 1997, 5, 1783-1788.
74. Pratt, R.F. Inhibition of a class C beta-lactamase by a specific phosphonate monoester. Science 1989, 246, 917-919.
75. Rahil, J.; Pratt, R.F. Phosphonate monoester inhibitors of class A beta-lactamases. Biochem. J. 1991, 275, 793-795.
76. Chen, C.C.; Rahil, J.; Pratt, R.F.; Herzberg, O. Structure of a phosphonate-inhibited beta-lactamase: An analog of the tetrahedral transition state/intermediate of beta-lactam hydrolysis. J. Mol. Biol. 1993, 234, 165-178.
77. Lobkovsky, E.; Billings, E.M.; Moews, P.C.; Rahil, J.; Pratt, R.F.; Knox, J.R. Crystallographic structure of a phosphonate derivative of the Enterobacter cloacae P99 cephalosporinase: Mechanistic interpretation of a beta-lactamase transition-state analog. Biochemistry 1994, 33, 6762-6772.
78. Maveyraud, L.; Pratt, R.F.; Samama, J.P. Crystal structure of an acylation transition-state analog of the TEM-1 beta-lactamase: Mechanistic implications for class A beta-lactamases. Biochemistry 1998, 37, 2622-2628.
79. Morrison, M.J.; Li, N.; Pratt, R.F. Inverse acyl phosph(on)ates: Substrates or inhibitors of beta-lactam-recognizing enzymes? Bioorg. Chem. 2001, 29, 271-281.
80. Pratt, R.F.; Hammar, N.J. Salicyloyl Cyclic Phosphate, a "Penicillin-Like" Inhibitor of β-Lactamases. J. Am. Chem. Soc. 1998, 120, 3004-3006.
81. Silvaggi, N.R.; Kaur, K.; Adediran, S.A.; Pratt, R.F.; Kelly, J.A. Toward Better Antibiotics: Crystallographic Studies of a Novel Class of DD-Peptidase/β-Lactamase Inhibitors. Biochemistry 2004, 43, 7046-7053.
82. Perumal, S.K.; Pratt, R.F. Synthesis and evaluation of ketophosph(on)ates as beta-lactamase inhibitors. J. Org. Chem. 2006, 71, 4778-4785.
83. Stefanova, M.E.; Davies, C; Nicholas, R.A.; Gutheil, W.G. pH, Inhibitor, And substrate specificity studies on Escherichia coli penicillin-binding protein 5. Biochim. Biophys. Acta 2002, 1597, 292-300.
84. Beck, J.; Gharbi, S.; Herteg-Fernea, A.; Vercheval, L.; Bebrone, C; Lassaux, P.; Zervosen, A.; Marchand-Brynaert, J. Aminophosphonic Acids and Aminobis(phosphonic acids) as Potential Inhibitors of Penicillin-Binding Proteins. Eur. J. Org. Chem. 2009, 85-97.
85. Jungheim, L.N.; Ternansky, R.J. Non-beta-lactam mimics of beta-lactam antibiotics. In The Chemistry of Beta-Lactams; Page, M.I., Ed.; Chapman and Hall: London, UK, 1992; pp. 306-324.
86. Imming, P.; Klar, B.; Dix, D. Hydrolytic stability versus ring size in lactams: Implications for the development of lactam antibiotics and other serine protease inhibitors. J. Med. Chem. 2000, 43, 4328-4331.
87. Baldwin, J.E.; Lynch, G.P.; Pitlik, J. Gamma-lactam analogues of beta-lactam antibiotics. J. Antibiot. 1991, 44, 1-24.
88. Marchand-Brynaert, J.; Ghosez, L. Non-beta-lactam analogs of penicillins and cephalosporins. In Recent Progress in the Chemical Synthesis of Antibiotics; Ohno, M., Lukais, G, Eds.; Springer-Verlag: Berlin, Germany, 1990; pp. 729-794.
89. Aszodi, J.; Rowlands, D.A.; Mauvais, P.; Collette, P.; Bonnefoy, A.; Lampilas, M. Design and synthesis of bridged gamma-lactams as analogues of beta-lactam antibiotics. Bioorg. Med. Chem. Lett. 2004, 14, 2489-2492.
90. Panfil, I.; Urbahczyk-Lipkowska, Z.; Chmielewski, M. Isoxazolidin-5-one analogs of β-lactam antibiotics. Carbohyd. Res. 1998, 306, 505-515.
91. Cao, X.; Iqbal, A.; Patel, A.; Gretz, P.; Huang, G; Crowder, M.; Day, R.A. 3-alkoxy-5-isoxazolidinones mimic beta-lactams. Biochem. Biophys. Res. Commun. 2003, 311, 267-271.
92. Bonnefoy, A.; Dupuis-Hamelin, C; Steier, V.; Delachaume, C; Seys, C; Stachyra, T.; Fairley, M.; Guitton, M.; Lampilas, M. In vitro activity of AVE1330A, An innovative broad-spectrum non-beta-lactam beta-lactamase inhibitor. J. Antimicrob. Chemother. 2004, 54, 410-417.
93. Allen, N.E.; Hobbs, J.N., Jr.; Preston, D.A.; Turner, J.R.; Wu, C.Y. Antibacterial properties of the bicyclic pyrazolidinones. J. Antibiot. 1990, 43, 92-99.
94. Harada, S.; Tsubotani, S.; Hida, T.; Ono, H.; Okazaki, H. Structure of lactivicin, An antibiotic having a new nucleus and similar biological activities to β-lactam antibiotics. Tetrahedron Lett. 1986, 27, 6229-6232.
95. Nozaki, Y.; Katayama, N.; Harada, S.; Ono, H.; Okazaki, H. Lactivicin, A naturally occurring non-beta-lactam antibiotic having beta-lactam-like action: Biological activities and mode of action. J. Antibiot. 1989, 42, 84-93.
96. Nozaki, Y.; Katayama, N.; Ono, H.; Tsubotani, S.; Harada, S.; Okazaki, H.; Nakao, Y. Binding of a non-beta-lactam antibiotic to penicillin-binding proteins. Nature 1987, 325, 179-180.
97. Harada, S.; Tsubotani, S.; Hida, T.; Koyana, K.; Kondo, M.; Ono, H. Chemistry of a new antibiotic: Lactivicin. Tetrahedron 1988, 44, 6589-6606.
98. Natsugari, H.; Kawano, Y.; Morimoto, A.; Yoshioka, K.; Ochiai, M. Synthesis of lactivicin and its derivatives. J. Chem. Soc. Chem. Commun. 1987, 62-63.
99. Tamura, N.; Matsushita, Y.; Kawano, Y.; Yoshioka, K. Synthesis and antibacterial activity of lactivicin derivatives. Chem. Pharm. Bull. 1990, 38, 116-122.
100. Macheboeuf, P.; Fischer, D.S.; Brown, T., Jr.; Zervosen, A.; Luxen, A.; Joris, B.; Dessen, A.; Schofield, C.J. Structural and mechanistic basis of penicillin-binding protein inhibition by lactivicins. Nat. Chem. Biol. 2007, 3, 565-569.
101. Grant, E.B.; Guiadeen, D.; Baum, E.Z.; Foleno, B.D.; Jin, H.; Montenegro, D.A.; Nelson, E.A.; Bush, K.; Hlasta, D.J. The synthesis and SAR of rhodanines as novel class C beta-lactamase inhibitors. Bioorg. Med. Chem. Lett. 2000, 10, 2179-2182.
102. Miguet, L.; Zervosen, A.; Gerards, T.; Pasha, F.A.; Luxen, A.; Disteche-Nguyen, M.; Thomas, A. Discovery of new inhibitors of resistant Streptococcus pneumoniae penicillin binding protein (PBP) 2x by structure-based virtual screening. J. Med. Chem. 2009, 52, 5926-5936.
103. Turk, S.; Verlaine, O.; Gerards, T.; Zivec, M.; Humljan, J.; Sosic, I.; Amoroso, A.; Zervosen, A.; Luxen, A.; Joris, B.; et al. New noncovalent inhibitors of penicillin-binding proteins from penicillin-resistant bacteria. PLoS One 2011, 6, e19418.
104. Sosic, I.; Turk, S.; Sinreith, M.; Trost, N.; Verlaine, O.; Amoroso, A.; Zervosen, A.; Luxen, A.; Joris, B.; Gobec, S. Exploration of the chemical space of novel naphthalene-sulfonamide and anthranilic acid-based inhibitors of penicillin-binding proteins. Acta Chim. Slov. 2012, 59, 380-388.
105. Phichith, D.; Bun, S.; Padiolleau-Lefevre, S.; Guellier, A.; Banh, S.; Galleni, M.; Frere, J.M.; Thomas, D.; Friboulet, A.; Avalle, B. Novel peptide inhibiting both TEM-1 beta-lactamase and penicillin-binding proteins. FEBS J. 2010, 277, 4965-4972.
106. Shilabin, A.G.; Dzhekieva, L.; Misra, P.; Jayaram, B.; Pratt, R.F. 4-Quinolones as Noncovalent Inhibitors of High Molecular Mass Penicillin-Binding Proteins. ACS Med. Chem. Lett. 2012, 3, 592-595.